Phase 1 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older.
- People with hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- aBC) whose cancer has grown or spread during or after at least one hormonal treatment combined with a specific type of targeted therapy called a CDK4/6 inhibitor, plus at least one other treatment, and for whom no standard treatment options remain (this applies to the dose escalation part of the trial).
- People with HR+/HER2- advanced breast cancer whose cancer has grown or spread during or after hormonal treatment combined with a CDK4/6 inhibitor, who have had no more than two prior hormonal treatment regimens for advanced disease, and who have not previously received chemotherapy or antibody-drug treatments for advanced disease (this applies to the dose expansion part of the trial).
Who may not be able to join:
- People whose bone marrow or organ function (such as liver or kidneys) is not working well enough, based on blood test results.
- People with serious heart problems or significantly reduced heart function.
- People currently using hormone replacement therapy.
- Women who could become pregnant but are unwilling to use highly effective contraception, as well as women who are pregnant or breastfeeding.
- For the combination treatment parts of the trial: people whose cancer has spread to internal organs and is causing symptoms, or whose overall disease burden means hormonal treatment would not be appropriate (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of dose-limiting toxicities (DLTs); Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs); Frequency of dose interruptions, reductions and discontinuations; Dose intensity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.